{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:54:31Z","timestamp":1761990871940,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jgar.2016.02.005","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T01:48:20Z","timestamp":1459907300000},"page":"50-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004\u20132014"],"prefix":"10.1016","volume":"6","author":[{"given":"Francesc","family":"Marco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2016.02.005_bib0160","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1086\/499406","article-title":"The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs","volume":"42","author":"Cosgrove","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.02.005_bib0165","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1086\/592412","article-title":"Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies","volume":"29","author":"Patel","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2016.02.005_bib0170","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1469-0691.2009.02902.x","article-title":"Cost of bacteraemia caused by methicillin-resistant vs. methicillin-susceptible Staphylococcus aureus in Spain: a retrospective cohort study","volume":"16","author":"Rubio-Terr\u00e9s","year":"2010","journal-title":"Clin Microbiol Infect"},{"year":"2011","series-title":"Antimicrobial resistance surveillance in Europe, 2011. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","key":"10.1016\/j.jgar.2016.02.005_bib0175"},{"year":"2012","series-title":"ECDC surveillance report. Surveillance of antimicrobial consumption in Europe, 2012","author":"European Centre for Disease Prevention and Control","key":"10.1016\/j.jgar.2016.02.005_bib0180"},{"year":"2013","series-title":"Antimicrobial resistance surveillance in Europe, 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","author":"European Centre for Disease Prevention and Control","key":"10.1016\/j.jgar.2016.02.005_bib0185"},{"key":"10.1016\/j.jgar.2016.02.005_bib0190","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1469-0691.2007.01943.x","article-title":"Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the Tigecycline Evaluation and Surveillance Trial","volume":"14","author":"Rodloff","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2016.02.005_bib0195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1179\/1120009X12Z.00000000016","article-title":"Antimicrobial susceptibility among E. faecalis and E. faecium from France, Germany, Italy, Spain and the UK (T.E.S.T. Surveillance Study, 2004\u20132009)","volume":"24","author":"Aznar","year":"2012","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2016.02.005_bib0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijantimicag.2009.02.003","article-title":"Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004\u20132007)","volume":"34","author":"N\u00f8rskov-Lauritsen","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2016.02.005_bib0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jgar.2014.05.001","article-title":"Antimicrobial susceptibility among Gram-positive and Gram-negative isolates collected in Europe between 2004 and 2010","volume":"2","author":"Denis","year":"2014","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2016.02.005_bib0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2047-2994-3-36","article-title":"A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012","volume":"3","author":"Cattoir","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"year":"2012","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014ninth edition. Document M07-A9","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.jgar.2016.02.005_bib0215"},{"year":"2014","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0","author":"European Committee on Antimicrobial Susceptibility Testing","key":"10.1016\/j.jgar.2016.02.005_bib0220"},{"year":"2014","series-title":"Antimicrobial resistance: global report on surveillance","author":"World Health Organization","key":"10.1016\/j.jgar.2016.02.005_bib0225"},{"key":"10.1016\/j.jgar.2016.02.005_bib0230","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"S\u00e1nchez Garc\u00eda","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2016.02.005_bib0235","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/650574","article-title":"Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus","volume":"50","author":"Morales","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2016.02.005_bib0240","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1128\/AAC.01464-06","article-title":"Global challenge of multidrug-resistant Acinetobacter baumannii","volume":"51","author":"Perez","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2016.02.005_bib0245","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1469-0691.2005.01184.x","article-title":"Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection","volume":"11","author":"del Mar Tomas","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2016.02.005_bib0250","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2016.02.005_bib0255","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/49.3.479","article-title":"Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)","volume":"49","author":"Henwood","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2016.02.005_bib0260","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-0711-7-4","article-title":"In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy","volume":"7","author":"Mezzatesta","year":"2008","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2016.02.005_bib0265","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/AAC.46.3.892-895.2002","article-title":"In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain","volume":"46","author":"Betriu","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2016.02.005_bib0270","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1179\/joc.2006.18.4.440","article-title":"Linezolid-resistant Enterococcus faecalis: first report in Spain","volume":"18","author":"S\u00e1nchez-G\u00f3mez","year":"2006","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2016.02.005_bib0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.diagmicrobio.2009.06.010","article-title":"Nosocomial outbreak of linezolid-resistant Enterococcus faecalis infection in a tertiary care hospital","volume":"65","author":"G\u00f3mez-Gil","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.02.005_bib0280","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/mdr.2013.0034","article-title":"Emergence and long-lasting persistence of linezolid-resistant Enterococcus faecium-ST117 in an oncohematologic patient after a nine-day course of linezolid","volume":"20","author":"S\u00e1nchez-D\u00edaz","year":"2014","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2016.02.005_bib0285","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2807\/ese.13.47.19046-en","article-title":"Emergence and spread of vancomycin resistance among enterococci in Europe","volume":"13","author":"Werner","year":"2008","journal-title":"Eur Surveill"},{"key":"10.1016\/j.jgar.2016.02.005_bib0290","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eimc.2008.09.006","article-title":"Extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals: 2nd multicenter study (GEIH-BLEE project, 2006)","volume":"27","author":"D\u00edaz","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"Suppl. 4","key":"10.1016\/j.jgar.2016.02.005_bib0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0213-005X(14)70170-3","article-title":"Evolution of carbapenemase-producing Enterobacteriaceae at the global and national level: what should be expected in the future?","volume":"32","author":"Oteo","year":"2014","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.jgar.2016.02.005_bib0300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jinf.2015.10.008","article-title":"Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain","volume":"72","author":"Palacios-Baena","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2016.02.005_bib0305","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.diagmicrobio.2006.07.005","article-title":"Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study","volume":"56","author":"Betriu","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2016.02.005_bib0310","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/jac\/dkp475","article-title":"Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY\u2013HasF efflux system also active against ciprofloxacin and cefpirome","volume":"65","author":"Hornsey","year":"2010","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716516300236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716516300236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T04:46:16Z","timestamp":1655441176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716516300236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":31,"alternative-id":["S2213716516300236"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2016.02.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"type":"print","value":"2213-7165"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004\u20132014","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2016.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}